Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Clearmind Medicine Inc.

< Previous 1 2 3 4 Next >
News headline image
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Closes US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Closes US$3.5 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.